Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.
Pfizer’s partner BioNTech boosted the 2021 delivery target for their Covid-19 vaccine to 2 billion doses, up from 1.3 billion previously, as they bring new production lines on stream and as more doses can be extracted per vial.
Covid-19 patients should take two doses of the Pfizer and BioNTech vaccine within a period of 21-28 days, the World Health Organization said as many countries grappled with a more highly infectious coronavirus variant.
Apex Innovative Sciences and the company’s affiliates announced their participation in three Covid-19 vaccine studies.
The Centers for Disease Control and Prevention had administered 2,589,125 first doses of Covid-19 vaccines in the United States as of the morning of Dec. 30 and distributed 12,409,050 doses.
The European Union was asked to allow an extra dose of the Covid-19 vaccine developed by Pfizer and BioNTech to be taken from each vial, a practice allowed elsewhere that would make scarce supplies go further.
A vaccine being developed by the Nanovaccine Institute at Iowa State University (ISU) will be able to be administered without needles and in one dose.
Europe launched a cross-border vaccination program of unprecedented scale on Dec. 27 as part of efforts to end the Covid-19 pandemic that has crippled economies and claimed more than 1.7 million lives around the world.
Millions of Covid-19 vaccines were sitting unused in U.S. hospitals and elsewhere a week into the massive inoculation campaign, putting the government’s target for 20 million vaccinations during December in doubt.
Pfizer and BioNTech reached an agreement with the Trump administration on supplying more of their Covid-19 vaccine.